Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report Q3, 2018

NefIgArd Phase 3-study initiated according to plan“This quarter, the company went into execution mode with regards to the preparations related to our clinical Phase 3 study NefIgArd. We were excited to get going after receiving the necessary funds in July. We have been submitting requests for approval to ethic committees, negotiated contracts with clinics and continued to tie up the hundreds of ends required in order to initiate such a large, global study. With 19 countries and 149 sites, we believe that this is one of largest clinical studies to be managed out of Sweden today. Based on

Scania Interim Report January-September 2018

Summary of the first nine months of 2018 · Operating income amounted to SEK 10,153 m. (9,080) · Net sales increased by 11 percent to SEK 98,674 m. (89,111) · Cash flow amounted to SEK -134 m. (3,002) in Vehicles and Services · The period was affected by major disruptions in the supply chain resulting in negative cash flow · As from the 2018 financial year, the presentation of the income statement has been adjusted to align with Volkswagen Group’s (including comparative periods)Comments by Henrik Henriksson, President and CEO “Demand for the new truck range remained

Pihlajalinna Interim Report 1 January–30 September 2018 (9 months)

Pihlajalinna Plc     Interim Report     1 November 2018 at 8.00 a.m. Pihlajalinna Interim Report 1 January–30 September 2018 (9 months) Pihlajalinna’s profitability is improving, outlook unchanged Brief look at July–September: · Revenue amounted to EUR 116.3 (99.4) million – an increase of 17.0 per cent · EBITDA amounted to EUR 10.7 (9.1) million · Adjusted EBITDA was EUR 10.7 (9.0) million – an increase of 18.3 per cent · Operating profit (EBIT) was EUR 5.9 (5.5) million · Adjusted operating profit (EBIT) was EUR 5.9 (5.4) million – an increase of 10.8 per cent

Targovax ASA: Third quarter 2018 results

Oslo, Norway, 1 November 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2018 results.Targovax's management will host an online presentation for investors, analysts and the press at 08:45 CET. The presentation in Norwegian can be followed here , or at: https://www.facebook.com/AXExposure/videos/279295392691286/ An English version can be found on Targovax Events & Presentations 

Nel ASA: Third Quarter 2018 Results

(Oslo, November 1, 2018) Nel ASA (“Nel”) reported revenues in the third quarter of 2018 of NOK 116.0 million, up from NOK 111.7 million in the third quarter of 2017. Nel received several purchase orders during the quarter, recently announced the construction of the world’s largest electrolyzer manufacturing plant and reiterates a strong market outlook. “The third quarter of 2018 was a hectic quarter, reflecting both the momentum we are gaining across the world, as well as our ambitions for the future. This includes announcing the construction of the world’s largest electrolyzer plant in

NGEX SHARE CAPITAL AND VOTING RIGHTS UPDATE

VANCOUVER, BRITISH COLUMBIA--(October 31, 2018) /CNW/ – NGEx Resources Inc. ("NGEx" or the “Company”) (TSX: NGQ; NASDAQ Stockholm: NGQ), reports the following share capital and voting rights update in accordance with the Swedish Financial Instruments Trading Act. As a result of the issuance of 28,000 common shares pursuant to the terms of a previously announced credit facility, the number of issued and outstanding shares of the Company has increased to 227,659,153 common shares with voting rights as at October 31, 2018. Additional Information  This information is information that

Updated Share Capital and Voting Rights for BlackPearl

CALGARY, ALBERTA, Oct. 31, 2018 /CNW/ - BlackPearl Resources Inc. ("BlackPearl" or the "Company") (TSX: PXX) (NASDAQ Stockholm: PXXS) reports the following, in accordance with the Swedish Financial Instruments Trading Act: As a result of the exercise of stock options, as at October 31, 2018, the number of issued and outstanding shares of the Company is 337,263,507 common shares with voting rights. The information in this release is subject to the disclosure requirements of BlackPearl Resources Inc. under the Swedish Financial Instruments Trading Act. The information was submitted for

CONSORTIUM OF AFRICA OIL, DELONEX AND VITOL ANNOUNCES ACQUISITION OF PRODUCING ASSETS IN DEEPWATER NIGERIA

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES  All dollar amounts in this press release are USD unless otherwise indicated. VANCOUVER, October 31, 2018 /CNW/ A consortium led by Vitol and comprising Africa Oil Corp (“Africa Oil”) (25%), Delonex Energy Ltd. (“Delonex”) (25%) and Vitol Investment Partnership II Ltd. (“Vitol”) (50%), (collectively, the “Consortium”), is pleased to announce that it has entered into a Share Purchase Agreement (“SPA”) to acquire a 50% ownership interest in Petrobras Oil and Gas B.V. for $1.407 billion.

New Number of Shares and Votes in Tobii

The number of shares and votes in Tobii AB has increased by 132,852 as a result of exercise of warrants in accordance with the company’s incentive programs. Today, the last trading day of the month, there are in total 97,574,355 shares and votes in the company. After the increase, the share capital amounts to SEK 708,090.51. The increase in the number of shares is due to the exercise of warrants in accordance with the Company's incentive programs. This information is information that Tobii is obliged to make public pursuant to the Financial Instruments Trading Act. The information was

ExpreS2ion announces positive Phase I/IIa malaria vaccine trial results by The Jenner Institute, University of Oxford

Horsholm, Denmark, October 31 2018 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that The Jenner Institute of the University of Oxford presents positive results from its Phase I/IIa clinical studies with their RH5.1 blood-stage malaria vaccine at a scientific meeting in New Orleans. The vaccine, developed and manufactured using ExpreS2ion’s ExpreS2 platform, was shown to be safe and it is the first vaccine to demonstrate a reduction in the parasite multiplication rate following a blood-stage controlled human malaria infection.In the results it is concluded, that RH5.1 is

Change of number of shares and votes in Instalco

Pursuant to the Swedish Financial Instruments Trading Act (Sw. lagen (1991:980) om handel med finansiella instrument), Swedish companies whose shares are listed on a regulated market and who increases or reduces the total number of shares or votes in the company is to disclose such changes on the last trading day the same month.As of 31 October 2018, there are in total 48,129,867 shares and votes in Instalco Intressenter AB (“Instalco” or the “Company”). The change in number of shares and votes in the Company is a result of the board of directors’ decision to issue in total 132,846 new

Follicum AB reports top-line data from First-in-Man Scalp Study with FOL-005 against hair loss

Follicum AB ("Follicum" or "Company"), a biotech company that develops new drugs in two areas, hair loss and diabetes, today reports top-line data from the first phase IIa study with FOL-005 for the treatment of hair loss on scalp in patients. The phase IIa study examined the safety and therapeutic effect of different doses of the drug candidate FOL-005, administered as injections into the scalp 3 times per week. The results confirmed that the treatment was safe with minimal side effects reported. Furthermore, increased hair growth was measured at the highest dose. Follicum will now follow up

Fellow Finance Oyj – Manager´s Transactions

Person subject to the notification requirementName: Antoni AirikkalaPosition: Other management IssuerName: Fellow Finance OyjLEI: 743700442EXD5CC8AT33 Notification type: INITIAL NOTIFICATIONReference number: 743700442EXD5CC8AT33_20181031111557_3 Transaction date: 2018-29-10Venue: noneInstrument type: SHAREISIN: FI4000348974Nature of the transaction: RECEIPT OF SHARE-BASED INCENTIVE OR REMUNERATION Transaction details (1) Volume: 11 000 Unit price: 7,587 EUR Aggregated transactions (1) Volume: 11 000 Volume weighted average price: 7,587 EUR Fellow

New direct route to Krabi from Stockholm Arlanda with Norwegian inaugurated

This winter, Swedes will be able to fly non-stop to another long-haul destination in Thailand. Today Norwegian started their direct service to the popular holiday destination of Krabi with two weekly departures from Stockholm Arlanda Airport. Thailand continues to be a favourite destination for Swedes. Norwegian already flies non-stop to Bangkok, and with the new destination of Krabi, Swedish travellers will have even more opportunities to fly directly to Thailand during the winter season. Bangkok is a year-round destination, while Krabi is a winter route. Krabi is located 900 km south

Tethys Oil AB: Announcement of change in number of shares and votes in Tethys Oil

In October 2018, the number of shares and votes in Tethys Oil AB (publ) has changed due to exercise of warrants under the long term incentive program approved by the annual general meeting on 13 May 2015. The number of shares and votes in Tethys Oil has in October 2018 increased by 352,560 shares and votes. As per 31 October 2018, the total number of shares and votes in the company amounted to 35,896,310. For further information, please contactMagnus Nordin, Managing Director, phone +46 8 505 947 00orJesper Alm, CFO, phone +46 8 505 947 00---------------------------------------

UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 31.10.2018

United Bankers Corporation NOTIFICATION 31.10.2018 at 18:30 UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 31.10.2018          Date 31.10.2018Exchange transaction BuyShare class UNIAVAmount 261Average price/share 7.3500 EURHighest price/share 7.3500 EURLowest price/share 7.3500 EURTotal price 1 918.35 EUR The shares held by United Bankers Corporation on 31.10.2018: UNIAV 68,375 On behalf of United Bankers CorporationSkandinaviska Enskilda Banken AB (Publ) Antti

European High Growth Opportunities Securitization Fund requests conversion of convertible bonds

European High Growth Opportunities Securitization Fund has by notice to the board of directors of Cereno Scientific AB (publ) (“Cereno”) called upon its right to conversion of convertible bonds previously issued in accordance with the financing solution announced by Cereno through a press release on 19 March 2018.Cereno has received notification from European High Growth Opportunities Securitization Fund regarding conversion of convertible bonds into 269 230 class B shares in Cereno, corresponding to SEK 700 000 of the convertible loan. The conversion price per share is SEK 2,6. Upon

CYBER1 records highest quarterly revenue result of 14.04m EUR, with total year to date revenue growth of 113% and strong organic revenue growth of 69%

London United Kingdom – 31 October 2018 – Cyber Security 1 AB (Publ) (the “Company”) (“CYBER1”)  (Nasdaq First North: CYB1), an international leader in Cyber security, GRC is pleased to announce the Q3 2018 results. The Company has achieved its highest quarterly revenue since listing on Nasdaq First North, with revenues of 14.04m EUR. This brings CYBER1’s total year to date (YTD) revenues to 23.11m EUR, demonstrating 69% organic growth of 7.53m EUR and 113% overall total growth of 14.04m EUR versus the same period in 2017.Highlights ·  Total revenue growth increased by 113%, from 10.9m

Major League Baseball Players Alumni Association Brings Legends for Youth Baseball Clinic Series to Alameda, CA

Free youth baseball clinic to feature Shawon Dunston and other MLB AlumniColorado Springs, Colo. – Local youth will have an opportunity to play with their big league heroes at the Major League Baseball Players Alumni Association (MLBPAA) Legends for Youth baseball clinic series on Saturday, November 3, 2018. In conjunction with Alameda Little League , the free clinic features former Major League Baseball players who will teach baseball skills, drills and life lessons for approximately 200 local youth. Players attending* include two-time All-

Nordea Bank Abp’s financial reporting in 2019

Nordea Bank Abp – Stock exchange release – Financial calendar Nordea Bank Abp will publish the following financial reports in 2019: · Fourth Quarter and Year-end Results 2018, 6 February 2019 · First Quarter Results 2019, 30 April 2019 · Second Quarter Results and half-year 2019, 18 July 2019 · Third Quarter Results and January-September 2019, 24 October 2019 The Annual Report and Capital and Risk Management Report for 2018 will be published on Nordea’s website (www.nordea.com) in week 9, 2019. The Annual General Meeting of Nordea Bank Abp will be held in Helsinki on

DISCLOSURE OF TRADE

Geveran Trading Co. Limited ("Geveran"), a company indirectly controlled by trusts established by Mr. John Fredriksen for the benefit of his immediate family, has on  31st October 2018 acquired 260,000 shares in Axactor SE ("Axactor") at a purchase price of NOK 21.99 per share. Following the acquisition, Geveran will own 26,311,734 shares in Axactor which will constitute 17.04% of the shares and votes in Axactor. Geveran also holds 13,000,000 warrants exchangeable into 13,000,000 ordinary shares in Axactor (the "Warrants"). The Warrants entitles Geveran to subscribe Axactor shares at NOK

Cereno Scientific’s patent is granted in US for use of drug candidate CS1

Cereno Scientific today announces that the US Patent Office has granted the company’s patent application titled “Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation”. The granted patent provides Cereno Scientific with intellectual property rights for the company’s treatment concept and use of its drug candidate, CS1, in the US.“It’s very positive for us that we now have received final approval in the US, the world’s largest drug market — a market that, for drug-related treatment of thrombosis alone, had

Tunadal’s new planing mill inauguration – an investment of 80 million SEK.

SCA Woods new planing mill at Tunadal was on Wednesday, 31st of October, inaugurated. The investment in Tunadals planing mill of 80 million SEK means increased productivity and better prerequisites for product development and innovations.Image caption: Jerry Larsson, President of SCA Wood, inaugurates Tunadals planing mill by planing a unplanned board. Photo: Per-Anders Sjöquist/SCA The new planing mill comes with a lot of benefits, with new raw material intake, new splitting line and new packaging line our productivity increases and with the new technology, the pace of the

There are no items matching the current filter
There are no more items matching the current filter
Back to top